ЭФФЕКТИВНОСТЬ БОРТЕЗОМИБА ПРИ ЛЕЧЕНИИ БОЛЬНЫХ РЕЦИДИВИРУЮЩЕЙ И РЕФРАКТЕРНОЙ МНОЖЕСТВЕННОЙ МИЕЛОМОЙ (АНАЛИЗ РОССИЙСКИХ ДАННЫХ ИССЛЕДОВАНИЯ EVOBS) К. М. Абдулкадыров, С. В. Волошин, А. В. Шмидт, В. А. Шуваев ФГБУ Российский НИИ Гематологии И Трансфузиологии ФМБА, Санкт-Петербург Р Е З Ю М Е. В Настоящее Время Проводится Международное Наблюдательное Исследование

Summary. Interna tional non-interventional electronic observational study (eVOBS) is ongoing for prospective evaluation of the efficiency and clinical outcomes of bortezomib-based therapy for primary relapsing/refractory multiple myeloma (MM) in the ‘real-world’ clinical practice setting. A total of 691 patients were included in the study in Russia. The patients were observed for at least 3 years since the beginning of therapy. The patients received bortezomib as monotherapy or in combination with other drugs within the framework of the study. Overall response rate was 86.1%, complete response was attained in 33.9%, near complete response in 21%, partial response in 26.8%, and minimum response in 4.4%. The median survival has not been reached. These results indicate the efficiency and safety of bortezomib as monotherapy and in combination with other drugs in previously treated patients with relapsing/refractory MM.Key words: multiple myeloma, observation study, bortezomib Для корреспонденции